ATAI Life Sciences Archives

Psychedelics News

ATAI Life Sciences

Industry

8 Mar 2023

A Deeper Look at atai Life Sciences’ Corporate Update

atai Life Science has released its most recent corporate update, an opportunity to take a step back and see the full breadth of atai’s diverse set of programs....

By Microdose NewsDesk

Industry

6 Mar 2023

atai Life Sciences Announces Clinical Pipeline and Corporate Updates

Today we got some clarity as atai Life Sciences released a pipeline update....

By Jason Najum

Industry

10 Jan 2023

A Deeper Look at atai Life Sciences’ Company Update

atai Life Science has released its most recent corporate update....

By Jason Najum

Breaking News, Industry

6 Jan 2023

Atai Announces Disappointing Results in PCN-101 Phase 2a Trial

atai Life Sciences Phase 2a study of PCN-101 (R-ketamine) for treatment-resistant depression was the most anticipated milestone of the second part of 2022....

By Microdose NewsDesk

Join Our Newsletter for Exclusive Updates, Stories, and More

Industry

23 Dec 2022

2022 End of Year Review: atai Life Sciences

We take a brief look atai Life Sciences and what they’ve accomplished in 2022...

By Jason Najum

Industry

19 Dec 2022

Atai Initiates Phase 2b Trial of RL-007 for Schizophrenia

Atai's new phase 2b proof-of-concept trial will evaluate the novel compound, RL-007, for pro-cognitive effects in patients with Cognitive Impairment Associated with Schizophrenia (CIAS)....

By Microdose NewsDesk

Industry

11 Nov 2022

Atai Reports Q3 Financials and Business Update

atai Life Sciences has the biggest product portfolio in the psychedelics medicine space, with over a dozen programs running under a wide range of subsidiary companies....

By Microdose NewsDesk

Industry

26 Oct 2022

Atai Completes Enrollment of Phase 2a Trial for Depression

atai’s subsidiary, has completed enrollment of Phase 2a double-blind, placebo-controlled clinical trial of PCN-101 (R-ketamine) for treatment-resistant depression....

By Microdose NewsDesk

Industry

25 Oct 2022

A Deeper Look at Atai Life Sciences’ R&D Day

Today, atai Life Sciences (Nasdaq: ATAI) held its much anticipated R&D Day, where management and scientific leaders walked investors through the company’s diverse medical pipeline....

By James Hallifax

Follow us on social

Latest News

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

Professional Training in Psychedelic Medicine

Psychedelic medicine is reshaping the future of mental health care. From the power of microdosing LSD to the promise of MDMA in PTSD, the world of medical psychedelics offers transformative possibilities. Our comprehensive, CE-accredited course provides you with the knowledge and understanding you need to tap into this groundbreaking field.

WordPress Ads

No Result

View All Result